Development of inhibitors in haemophilia

Autor:	D. Savescu, L. Pop, L. Ritli, D. Mihailov, C. Petrovanu, E. Ursu, H. Ionita, V. Uscatescu, Margit Serban, A. Cucuianu, P. Stancu, Wolfgang Schramm, D. Baghiu, S. Talpos-Niculescu
Rok vydání:	2011
Předmět:	medicine.medical_specialty Continuous infusion business.industry Hematology Haemophilia medicine.disease Titer Internal medicine Epidemiology medicine Blood Coagulation Factor Inhibitors business Surgical interventions Factor IX medicine.drug
Zdroj:	Hämostaseologie. 31:S20-S23
ISSN:	2567-5761 0720-9355
Popis:	SummaryA number of 513 consecutive patients (494-haemophilia A and 19-haemophilia B) from eight haemophilia treatment centers have been investigated with Bethesda assay for the presence of factor VIII or IX inhibitors. The overall prevalence of inhibitors was 15.20%, 18.48% in severe, 5.60% in moderate and 12.24% in mild forms. The prevalence was higher than reported in most of the western countries. The age at start of substitution (p = 0.9775), the frequent switching of factor concentrates (p = 0.8931) were not relevant factors for the development of inhibitors. It is worth to be mentioned the unexpectedly occurrence of inhibitors in prior inhibitor negative (6/72) patients (during surgical interventions) probably due to their previous scarce substitution, occurrence which seems not being connected with the continuous infusion modality of factor VIII administration (p = 0.8341). In controversial situations, in the field of low titer (≤1 BU/ml) inhibitors for a reliable interpretation of the results the performance of recovery index and half-life time assessment of FVIII/IX was undertaken.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::b5457ffb4b1bd7bc4649bb75383874f0 https://doi.org/10.1055/s-0037-1619744 Zobrazit plný text záznamu